Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph Ciccolini

Showing results (11-20 of 168) with videos related to

Pageof 17
Sort By:
Pharmacogenomics|February 12, 2013
Severe or lethal toxicities with nucleosidic analogs: time for actionAlexandre Evrard, Bruno Lacarelle, Joseph Ciccolini
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2007
Genotype-based methods for anticipating gemcitabine-related severe toxicities may lead to false-negative resultsCédric Mercier, Alexandre Evrard, Joseph Ciccolini
Translational Oncology|December 1, 2020
The association between adverse events and outcome under checkpoint inhibitors: Where is the deal?Gerard Milano, Federico Innocenti, Joseph Ciccolini
Current Medicinal Chemistry. Anti-Cancer Agents|March 23, 2004
Thymidine phosphorylase and fluoropyrimidines efficacy: a Jekyll and Hyde storyJoseph Ciccolini, Alexandre Evrard, Pierre Cuq
Critical Reviews in Oncology/Hematology|July 23, 2013
Challenges, expectations and limits for nanoparticles-based therapeutics in cancer: a focus on nano-albumin-bound drugsRaphaelle Fanciullino, Joseph Ciccolini, Gérard Milano
Cancer Chemotherapy and Pharmacology|October 15, 2017
PRIMUM NON NOCERE: now and again an echo of DPD with capecitabineJoseph Ciccolini, Bruno Lacarelle, Gérard Milano
Expert Opinion on Drug Metabolism & Toxicology|January 8, 2026
Bringing 5-FU monitoring home: microsampling as the potential next step beyond DPD deficiency screeningManon Launay, Antonin Schmitt, Joseph Ciccolini
CPT: Pharmacometrics & Systems Pharmacology|February 27, 2021
Mechanistic models for hematological toxicities: Small is beautifulLaure Deyme, Sébastien Benzekry, Joseph Ciccolini
British Journal of Cancer|June 17, 2020
Deciphering the response and resistance to immune-checkpoint inhibitors in lung cancer with artificial intelligence-based analysis: when PIONeeR meets QUANTICJoseph Ciccolini, Sébastien Benzekry, Fabrice Barlesi
Bulletin Du Cancer|March 6, 2026
[Antibody drug conjugates: Use and optimization in HER2-negative metastatic breast cancers (triple negative, RH+/HER2-)]Mahasti Saghatchian, Joseph Ciccolini, Delphine Loirat
Pageof 17

Showing results (11-20 of 168) with videos related to

Sort By:
Pageof 17
Pharmacogenomics|February 12, 2013
Severe or lethal toxicities with nucleosidic analogs: time for actionAlexandre Evrard, Bruno Lacarelle, Joseph Ciccolini
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2007
Genotype-based methods for anticipating gemcitabine-related severe toxicities may lead to false-negative resultsCédric Mercier, Alexandre Evrard, Joseph Ciccolini
Translational Oncology|December 1, 2020
The association between adverse events and outcome under checkpoint inhibitors: Where is the deal?Gerard Milano, Federico Innocenti, Joseph Ciccolini
Current Medicinal Chemistry. Anti-Cancer Agents|March 23, 2004
Thymidine phosphorylase and fluoropyrimidines efficacy: a Jekyll and Hyde storyJoseph Ciccolini, Alexandre Evrard, Pierre Cuq
Critical Reviews in Oncology/Hematology|July 23, 2013
Challenges, expectations and limits for nanoparticles-based therapeutics in cancer: a focus on nano-albumin-bound drugsRaphaelle Fanciullino, Joseph Ciccolini, Gérard Milano
Cancer Chemotherapy and Pharmacology|October 15, 2017
PRIMUM NON NOCERE: now and again an echo of DPD with capecitabineJoseph Ciccolini, Bruno Lacarelle, Gérard Milano
Expert Opinion on Drug Metabolism & Toxicology|January 8, 2026
Bringing 5-FU monitoring home: microsampling as the potential next step beyond DPD deficiency screeningManon Launay, Antonin Schmitt, Joseph Ciccolini
CPT: Pharmacometrics & Systems Pharmacology|February 27, 2021
Mechanistic models for hematological toxicities: Small is beautifulLaure Deyme, Sébastien Benzekry, Joseph Ciccolini
British Journal of Cancer|June 17, 2020
Deciphering the response and resistance to immune-checkpoint inhibitors in lung cancer with artificial intelligence-based analysis: when PIONeeR meets QUANTICJoseph Ciccolini, Sébastien Benzekry, Fabrice Barlesi
Bulletin Du Cancer|March 6, 2026
[Antibody drug conjugates: Use and optimization in HER2-negative metastatic breast cancers (triple negative, RH+/HER2-)]Mahasti Saghatchian, Joseph Ciccolini, Delphine Loirat
Pageof 17